Stock NKTR NEKTAR THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

News Nektar Therapeutics

Equities

NKTR

US6402681083

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
1.76 USD +10.00% Intraday chart for Nektar Therapeutics +12.10% +211.50%
May. 09 Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M MT
May. 09 Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nektar: Q1 Earnings Snapshot
AQ
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M
MT
Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024
Nektar Therapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Nektar Therapeutics Reports First Quarter 2024 Financial Results
PR
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
PR
Nektar Therapeutics : SCHEDULE 14A
PU
Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
CI
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference
AQ
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
PR
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC
CI
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
MT
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating
MT
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
PR
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
CI
Transcript : Nektar Therapeutics, Q4 2023 Earnings Call, Mar 04, 2024
Nektar: Q4 Earnings Snapshot
AQ
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M
MT
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NKTR Stock
  4. News Nektar Therapeutics
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW